

## Medtronic to Acquire Invatec and Affiliated Companies

### *Acquisition Will Expand Product Offering and Pipeline for Cardiovascular Interventions*

MINNEAPOLIS, Jan 25, 2010 (BUSINESS WIRE) -- Moving to expand its impact on peripheral vascular disease, Medtronic, Inc. (NYSE:MDT), announced today that it has signed a definitive agreement to acquire Invatec, a developer of innovative medical technologies for the interventional treatment of cardiovascular disease, and two affiliated companies: Fogazzi, which provides polymer technology to Invatec; and Krauth Cardiovascular, which distributes Invatec products in Germany. The agreement calls for Medtronic to make an initial payment of \$350 million to Invatec and additional payments of up to \$150 million for Invatec's achievement of specific milestones.

Invatec's array of stents, angioplasty balloons and accessory products complement therapies and products in Medtronic's CardioVascular business, adding a robust peripheral franchise and pipeline, while enhancing its coronary product offering. Notably, Invatec has brought four drug-eluting balloons to market, covering the coronaries and lower-extremity vessels - the only company worldwide with this distinction. It is a pioneer in the development and commercialization of lesion-specific solutions, including therapies for below-the-knee and carotid artery disease.

"Medtronic's acquisition of Invatec will accelerate the growth of our CardioVascular business, adding important new products for the coronary and peripheral vascular markets," said Scott Ward, senior vice president at Medtronic and president of the CardioVascular business.

"Invatec brings to Medtronic an established international business with a European center of technology development and manufacturing, as well as a strong history of delivering products and high-value solutions to the interventional market," said Andrea Venturelli, co-founder, chief executive and technical officer of Invatec.

Invatec co-founder Stefan Widensohler, vice president of global sales and marketing, said, "Our integration into Medtronic creates a tremendous opportunity to leverage Medtronic's global scale and scope across geographies and functions, from R&D to sales and marketing, to advance the interventional treatment of cardiovascular disease."

Cardiovascular interventions represent the world's largest sector of the medical device market, generating \$10 billion annually on a global basis. A significant growth opportunity within this sector is peripheral vascular disease, a large and underserved market currently estimated at \$2 billion annually and growing faster than 10 percent per year. Approximately 20 million people in the United States and Western Europe alone suffer from peripheral vascular disease, which causes pain, reduces mobility, inhibits wound healing and leads to approximately 250,000 amputations per year. Together, Medtronic and Invatec will be better positioned to address these and other unmet clinical needs in the treatment of cardiovascular disease, the world's leading cause of death.

### About Invatec

Invatec (<http://www.invatec.com>) is an innovator in the development and commercialization of interventional coronary and peripheral products, with global headquarters in Europe. Driven by research and technology, Invatec actively collaborates with physicians and centers of excellence to develop products that will improve life

expectancy and quality of life for patients. The company's core competencies include polymer processing, metallurgy, surface treatments and drug coatings. Invatec is vertically integrated with full in-house capabilities to design, develop, manufacture and assemble its 35 product families currently offered in more than 70 countries. Dedicated to "making ideas come alive," the company was founded in 1996 by Andrea Venturelli and Stefan Widensohler, and employs approximately 900 people, predominantly in Brescia, Italy, and Frauenfeld, Switzerland.

#### About Medtronic

Medtronic, Inc. (<http://www.medtronic.com>), headquartered in Minneapolis, is a global leader in medical technology - alleviating pain, restoring health, and extending life for millions of people around the world. The CardioVascular business is committed to advancing the treatment of coronary, peripheral, aortic and structural heart disease through collaboration with leading clinicians, researchers and scientists worldwide.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's Annual Report on Form 10-K for the year ended April 24, 2009. Actual results may differ materially from anticipated results.

SOURCE: Medtronic, Inc.

Medtronic, Inc.

Public Relations:

Joe McGrath, 707-591-7367

Investor Relations:

Jeff Warren, 763-505-2696

---

<https://news.medtronic.com/2010-01-25-Medtronic-to-Acquire-Invatec-and-Affiliated-Companies>